WHO and CDC Officially Recognize Cannabinoid Hyperemesis Syndrome as ER Visits Surge
WHO and CDC officially recognize Cannabinoid Hyperemesis Syndrome (CHS), a severe vomiting disorder linked to chronic cannabis use, as ER visits for the condition surge.
Overview
Chronic cannabis users are at risk of Cannabinoid Hyperemesis Syndrome (CHS), a potentially deadly condition causing severe nausea, recurring vomiting, and intense cramps, often leading to serious health issues.
The WHO and CDC officially recognized Cannabinoid Hyperemesis Syndrome (CHS) in October, issuing a dedicated diagnostic code. This aids global health officials in better diagnosing and tracking the mysterious vomiting disorder.
CHS is linked to long-term marijuana use. THC potency in cannabis products has significantly increased from 5% in the 1990s to over 20% today, potentially contributing to the syndrome's rising prevalence.
CHS causes recurring intense cramps, nausea, and vomiting, often leading sufferers to seek urgent medical care. Ongoing symptoms like belly pain and weight loss underscore the condition's severity.
Emergency room visits for CHS surged during the COVID-19 pandemic and remain elevated. A recent study documented around 100,000 cases, highlighting a growing public health concern for chronic cannabis users.
Analysis
Center-leaning sources frame this story with a cautionary tone, emphasizing the "tradeoffs" and "not risk-free" aspects of cannabis use, particularly long-term and heavy consumption. They highlight the rise of cannabinoid hyperemesis syndrome (CHS) as a significant health concern, linking its increase to factors like growing legalization and higher THC levels, while still acknowledging cannabis's positive uses.